A number of labs and informatics firms are using test data to help guide the response to the virus in a spirit similar to that of initiatives like Lab 2.0.
The firm looks to win new customers among US providers while also partnering with IVD companies to embed its lab data analysis tools in their instruments.
Israel-based software company Medial EarlySign will work with Geisinger's innovation center to develop technologies to predict lower GI and other "high-burden" diseases.
The firm has developed a digital platform that determines whether patients meet guidelines for genetic testing, and if so, what test they should receive.
At the AGBT meeting last night, Johns Hopkins researcher Joshua Cohen said that the partners are looking to recruit 50,000 healthy individuals for the study.
